Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M14,292Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-475.8EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)20.9Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %1.6PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M100,000,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with XLV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XLVKen Fisher 2016-12-31 Add0.01%$66.02 - $72.2
($69.45)
$ 70.471%Add 15.21%393,127
XLVKen Fisher 2016-09-30 Add$71.38 - $75.68
($73.57)
$ 70.47-4%Add 4.23%341,214
XLVKen Fisher 2016-06-30 Add$67.78 - $72.68
($70.43)
$ 70.470%Add 9.61%327,373
XLVKen Fisher 2016-03-31 Add$63.52 - $72.03
($67.02)
$ 70.475%Add 1.75%298,675
XLVKen Fisher 2015-12-31 Add$66.86 - $72.99
($70.76)
$ 70.47-0%Add 2.64%293,541
XLVKen Fisher 2015-09-30 Add$64.29 - $77.22
($73.06)
$ 70.47-4%Add 5.33%285,985
XLVLeon Cooperman 2015-06-30 Sold Out -0.42%$71.46 - $76.45
($73.85)
$ 70.47-5%Sold Out0
XLVKen Fisher 2015-06-30 Add$71.71 - $76.45
($74.07)
$ 70.47-5%Add 5.40%271,515
XLVLeon Cooperman 2015-03-31 Buy 0.42%$67.86 - $74.9
($71.15)
$ 70.47-1%New holding366,000
XLVKen Fisher 2015-03-31 Add$68.05 - $74.9
($71.32)
$ 70.47-1%Add 4.15%257,614
XLVKen Fisher 2014-06-30 Add0.01%$55.71 - $61.23
($58.7)
$ 70.4720%Add 34.36%226,412
XLVGeorge Soros 2012-09-30 Sold Out -0.03%$37.27 - $40.3
($38.73)
$ 70.4782%Sold Out0
XLVGeorge Soros 2012-06-30 Buy 0.03%$35.52 - $37.87
($36.91)
$ 70.4791%New holding50,000
XLVKen Fisher 2012-06-30 Add$35.52 - $37.87
($36.91)
$ 70.4791%Add 53.52%119,754
XLVKen Fisher 2011-06-30 Buy 0.01%$33.28 - $36.42
($34.99)
$ 70.47101%New holding86,997
XLVGeorge Soros 2011-03-31 Sold Out $31.5 - $33.18
($32.33)
$ 70.47118%Sold Out0
XLVGeorge Soros 2010-12-31 Reduce-0.15%$30.19 - $31.78
($31.13)
$ 70.47126%Reduce -93.88%34,153
XLVGeorge Soros 2010-09-30 Buy 0.25%$28.03 - $30.68
($29.2)
$ 70.47141%New holding558,053
XLVGeorge Soros 2010-06-30 Sold Out $28.38 - $32.31
($30.13)
$ 70.47134%Sold Out0
XLVGeorge Soros 2010-03-31 Reduce$30.68 - $33
($31.72)
$ 70.47122%Reduce -43.59%6,600
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XLV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


XLV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.48643.25view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94315.94view
DINWOODIE, TYLER WAYNE PAULSenior Officer 2017-01-16Buy4,000$0.1741347.06view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.365080.88view
Bebek, IvanDirector 2017-01-16Buy8,990$3.381984.62view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4117085.37view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91152.45view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.271023.76view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.3816.69view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1546873.33view

Quarterly/Annual Reports about XLV:

    News about XLV:

    Articles On GuruFocus.com
    S&P 500 Sector ETFs: A Look Under the Hood, Part 3 Mar 11 2015 
    Build a “Whatever Happens” Portfolio – Now! Aug 15 2014 
    Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

    More From Other Websites
    UnitedHealth’s OptumHealth: Will It See Strong Revenue Growth? Jan 18 2017
    Biotech ETFs: When Will The Pain End? Jan 17 2017
    Sector Scorecard: Technology ETF Sets All-Time High on S&P Jan 17 2017
    Farr: Have to look at stocks on a stock-by-stock basis Jan 13 2017
    Farr: Washington's messy, and there's room to disappoint ... Jan 13 2017
    Behind Johnson & Johnson’s Recent Stock Performance Jan 13 2017
    Joe Tigay's Health Care SPDR ETF Options Trade Jan 12 2017
    Eli Lilly's stock rallies after appeals court upholds favorable patent ruling Jan 12 2017
    Trump Tries Recent Enthusiasm For Healthcare ETFs Jan 12 2017
    What Does the December Jobs Report Mean for the Economy? Jan 11 2017
    Healthcare Slammed As Trump Vows To Fight Drug Prices Jan 11 2017
    Biotech ETFs fall as Trump says more bidding needed on drugs Jan 11 2017
    Traders see floor in health-care fund Jan 11 2017
    Illumina's stock soars toward best gain in 5 years after upbeat sales outlook, product upgrade Jan 10 2017
    Technology Rules as Only S&P Sector Hitting a New High Jan 09 2017
    Zimmer Biomet Holdings: How’s Its Recent Stock Performance? Jan 06 2017
    The 'Super Bowl' for health care investors Jan 06 2017
    Analysts’ Recommendations for Zimmer Biomet Holdings Jan 06 2017
    How Do Wall Street Analysts View Becton Dickinson? Jan 05 2017
    Buy health care despite Obamacare battle? Jan 04 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)